Medford, MA, United States of America

Frano Irvine

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Immunitas Therapeutics, Inc.. Active years: 2025.

USPTO Granted Patents = 2 

% Patents Active = 100.0

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Frano Irvine: Innovator in Antibody Therapeutics

Introduction

Frano Irvine is a notable inventor based in Medford, MA (US), recognized for his contributions to the field of antibody therapeutics. He holds 2 patents that focus on innovative treatments for disorders associated with CD161, particularly in the context of certain cancers.

Latest Patents

Irvine's latest patents include the invention of anti-CD161 antibodies and their uses. This invention relates to the development of pharmaceutical compositions that comprise these antibodies, as well as methods for utilizing them to treat disorders mediated by CD161. The patents also cover expression vectors and host cells designed for the production of these antibodies, showcasing a significant advancement in therapeutic options for cancer treatment.

Career Highlights

Frano Irvine is currently associated with Immunitas Therapeutics, Inc., where he continues to push the boundaries of research in antibody therapies. His work is pivotal in the ongoing quest to develop effective treatments for challenging medical conditions.

Collaborations

Irvine collaborates with talented professionals in his field, including Alison Tisdale and Emily Rosentrater. These partnerships enhance the innovative potential of his research and contribute to the advancement of therapeutic solutions.

Conclusion

Frano Irvine's work in the development of anti-CD161 antibodies represents a significant contribution to the field of cancer therapeutics. His innovative approach and collaboration with other experts highlight the importance of teamwork in advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…